Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On...
Clinical Trial
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase...
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial DesignGLEN ALLEN, Va., June 11, 2025 (GLOBE...
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical...
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
Study met primary endpoint of safety and tolerability at all doses and secondary pharmacodynamic and pharmacokinetic endpoints after single subcutaneous...
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE,...
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from...
Ocugen To Present at BIO International Convention 2025
MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader...
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trialBURLINGTON,...
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by JuvenaCollaboration...
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared...
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory...
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing...
Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.
Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and...
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”)...
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today...
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
MELBOURNE, Australia and INDIANAPOLIS, June 11, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”)...
Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month
Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign...